Literature DB >> 10402074

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ).

J Ruof1, P Brühlmann, B A Michel, G Stucki.   

Abstract

OBJECTIVE: To develop a self-administered systemic sclerosis questionnaire (SySQ) covering condition-specific functional limitation and symptoms. METHODS An initial item pool was generated by open patient interviews. A preliminary questionnaire was devised using 62 systemic sclerosis (SSc; scleroderma) patients. Factor analysis was used for further selection and grouping of items into distinct scales. The retrieved scales were tested for internal consistency and test-retest reliability. Spearman's rank correlation and Wilcoxon's rank sum test were used to examine hypothesized associations of the SySQ with various clinical and laboratory features.
RESULTS: Altogether 32 SySQ items were selected and aggregated into 12 scales addressing 'pain', 'stiffness', 'coldness', 'complex functions', 'strength of hands', 'rising', 'walking', shortness of breath', 'upper airway symptoms', 'eating', 'swallowing' and 'heartburn/regurgitation'. Internal consistency ranged from 0.93 ('complex functions') to 0.73 ('heartburn/regurgitation'); Spearman's correlation coefficient for test retest reliability ranged from 0.93 to 0.73 (P < 0.001). While the scales were associated with corresponding functional impairments, there was generally less association with morphological impairments.
CONCLUSION: The SySQ is a valid and reliable condition-specific measure in patients with SSc. Individually applicable scales cover a wide spectrum of general and organ-specific SSc symptoms and functional limitation. After further validation with respect to its ability to measure change, it may be used in clinical, health services and epidemiological research.

Entities:  

Mesh:

Year:  1999        PMID: 10402074     DOI: 10.1093/rheumatology/38.6.535

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

1.  Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ).

Authors:  C Georges; O Chassany; L Mouthon; K Tiev; C Toledano; O Meyer; Z Marjanovic; C Heneggar; T Papo; B Crickx; D Sereni; J Cabane; D Farge
Journal:  Clin Rheumatol       Date:  2004-06-23       Impact factor: 2.980

2.  Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ).

Authors:  Luiza F Rocha; Roberta G Marangoni; Percival D Sampaio-Barros; Mauricio Levy-Neto; Natalino H Yoshinari; Eloisa Bonfa; Virginia Steen; Sergio C Kowalski
Journal:  Clin Rheumatol       Date:  2013-08-22       Impact factor: 2.980

Review 3.  Assessment of skin involvement in systemic sclerosis.

Authors:  Gábor Kumánovics; Márta Péntek; Sangmee Bae; Daniela Opris; Dinesh Khanna; Daniel E Furst; László Czirják
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

4.  The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis.

Authors:  P Ostojić; N Damjanov
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

Review 5.  [Patient-centered assessment of functional health in systemic sclerosis -- where are we now?].

Authors:  T Sigl; T Ewert; G Stucki
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

6.  Clinical validity of the SWAL-QOL and SWAL-CARE outcome tools with respect to bolus flow measures.

Authors:  Colleen A McHorney; Bonnie Martin-Harris; JoAnne Robbins; John Rosenbek
Journal:  Dysphagia       Date:  2006-07       Impact factor: 3.438

7.  The symptom burden index: development and initial findings from use with patients with systemic sclerosis.

Authors:  Michael A Kallen; Maureen D Mayes; Yana L Kriseman; Sofia B de Achaval; Vanessa L Cox; Maria E Suarez-Almazor
Journal:  J Rheumatol       Date:  2010-06-01       Impact factor: 4.666

8.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

Review 9.  Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Authors:  Ulrich A Walker; Philip J Clements; Yannick Allanore; Oliver Distler; Chester V Oddis; Dinesh Khanna; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

10.  Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries.

Authors:  Tanja A Stamm; Malin Mattsson; Carina Mihai; Juliane Stöcker; Alexa Binder; Bettina Bauernfeind; Georg Stummvoll; Gunvor Gard; Roger Hesselstrand; Gunnel Sandqvist; Oana Draghicescu; Ana Maria Gherghe; Malina Voicu; Klaus P Machold; Oliver Distler; Josef S Smolen; Carina Boström
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.